Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 10.33
FOLD's Cash to Debt is ranked lower than
57% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. FOLD: 10.33 )
Ranked among companies with meaningful Cash to Debt only.
FOLD' s 10-Year Cash to Debt Range
Min: 4.97  Med: 51.24 Max: N/A
Current: 10.33
F-Score: 2
Z-Score: 5.31
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -6302.12
FOLD's Operating margin (%) is ranked lower than
90% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. FOLD: -6302.12 )
Ranked among companies with meaningful Operating margin (%) only.
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72  Med: -1430.62 Max: -11.42
Current: -6302.12
-17680.72
-11.42
Net-margin (%) -6312.99
FOLD's Net-margin (%) is ranked lower than
91% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. FOLD: -6312.99 )
Ranked among companies with meaningful Net-margin (%) only.
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82  Med: -1286.28 Max: -10.2
Current: -6312.99
-16427.82
-10.2
ROE (%) -114.69
FOLD's ROE (%) is ranked lower than
83% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. FOLD: -114.69 )
Ranked among companies with meaningful ROE (%) only.
FOLD' s 10-Year ROE (%) Range
Min: -319.35  Med: -88.03 Max: -9.19
Current: -114.69
-319.35
-9.19
ROA (%) -50.94
FOLD's ROA (%) is ranked lower than
69% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. FOLD: -50.94 )
Ranked among companies with meaningful ROA (%) only.
FOLD' s 10-Year ROA (%) Range
Min: -3515.77  Med: -50.19 Max: -6.13
Current: -50.94
-3515.77
-6.13
ROC (Joel Greenblatt) (%) -2374.69
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. FOLD: -2374.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1978.21  Med: -1314.93 Max: -134.99
Current: -2374.69
-1978.21
-134.99
Revenue Growth (3Y)(%) -68.20
FOLD's Revenue Growth (3Y)(%) is ranked lower than
88% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. FOLD: -68.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FOLD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -68.20 Max: -2.6
Current: -68.2
EBITDA Growth (3Y)(%) -12.40
FOLD's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. FOLD: -12.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FOLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -13.40 Max: 82.8
Current: -12.4
0
82.8
EPS Growth (3Y)(%) -10.10
FOLD's EPS Growth (3Y)(%) is ranked lower than
53% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. FOLD: -10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FOLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.2  Med: -14.20 Max: 59.5
Current: -10.1
-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

FOLD Guru Trades in Q2 2014

George Soros 70,500 sh (New)
Jim Simons Sold Out
RS Investment Management Sold Out
Charles Brandes Sold Out
Chuck Royce 283,700 sh (-9.56%)
» More
Q3 2014

FOLD Guru Trades in Q3 2014

Charles Brandes 36,700 sh (New)
RS Investment Management 1,248,215 sh (New)
Steven Cohen 195,900 sh (New)
Paul Tudor Jones 78,079 sh (New)
Jim Simons 130,400 sh (New)
Chuck Royce Sold Out
George Soros Sold Out
» More
Q4 2014

FOLD Guru Trades in Q4 2014

Louis Moore Bacon 225,000 sh (New)
Jim Simons 508,700 sh (+290.11%)
RS Investment Management 2,850,955 sh (+128.40%)
Paul Tudor Jones 98,522 sh (+26.18%)
Steven Cohen Sold Out
Charles Brandes Sold Out
» More
Q1 2015

FOLD Guru Trades in Q1 2015

Steven Cohen 173,900 sh (New)
Jim Simons Sold Out
RS Investment Management 2,564,545 sh (-10.05%)
Louis Moore Bacon 140,641 sh (-37.49%)
Paul Tudor Jones 11,620 sh (-88.21%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.00
FOLD's P/B is ranked lower than
85% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. FOLD: 13.00 )
Ranked among companies with meaningful P/B only.
FOLD' s 10-Year P/B Range
Min: 0.87  Med: 3.25 Max: 14.42
Current: 13
0.87
14.42
P/S 1403.00
FOLD's P/S is ranked lower than
98% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. FOLD: 1403.00 )
Ranked among companies with meaningful P/S only.
FOLD' s 10-Year P/S Range
Min: 0.84  Med: 12.53 Max: 1434
Current: 1403
0.84
1434
Current Ratio 7.19
FOLD's Current Ratio is ranked higher than
64% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. FOLD: 7.19 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s 10-Year Current Ratio Range
Min: 3.46  Med: 7.74 Max: 18.26
Current: 7.19
3.46
18.26
Quick Ratio 7.19
FOLD's Quick Ratio is ranked higher than
65% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. FOLD: 7.19 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s 10-Year Quick Ratio Range
Min: 3.46  Med: 7.74 Max: 18.26
Current: 7.19
3.46
18.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.63
FOLD's Price/Net Cash is ranked lower than
77% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. FOLD: 22.63 )
Ranked among companies with meaningful Price/Net Cash only.
FOLD' s 10-Year Price/Net Cash Range
Min: 1.06  Med: 3.70 Max: 148.75
Current: 22.63
1.06
148.75
Price/Net Current Asset Value 21.58
FOLD's Price/Net Current Asset Value is ranked lower than
80% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. FOLD: 21.58 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
FOLD' s 10-Year Price/Net Current Asset Value Range
Min: 1.02  Med: 3.51 Max: 99.17
Current: 21.58
1.02
99.17
Price/Tangible Book 19.49
FOLD's Price/Tangible Book is ranked lower than
88% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. FOLD: 19.49 )
Ranked among companies with meaningful Price/Tangible Book only.
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96  Med: 3.38 Max: 54.09
Current: 19.49
0.96
54.09
Price/Median PS Value 107.92
FOLD's Price/Median PS Value is ranked lower than
100% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. FOLD: 107.92 )
Ranked among companies with meaningful Price/Median PS Value only.
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 1.10 Max: 83.69
Current: 107.92
0.07
83.69
Earnings Yield (Greenblatt) (%) -6.37
FOLD's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. FOLD: -6.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FOLD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.37  Med: 139.40 Max: 3784.9
Current: -6.37
-6.37
3784.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Other Websites
Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes Jun 29 2015
Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes Jun 29 2015
Mid-Morning Market Update: Markets Gain; Finish Line Beats Q1 Views Jun 26 2015
Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by... Jun 25 2015
Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by... Jun 25 2015
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX)... Jun 25 2015
Keep An Eye On These 10 After-Hours Movers Jun 25 2015
Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers Jun 17 2015
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of... Jun 17 2015
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of... Jun 17 2015
Amicus Therapeutics (FOLD) in Focus: Stock Gains 7.9% - Tale of the Tape Jun 15 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 12 2015
Amicus Jumps to Seven-Year High After $225 Million Share Sale Jun 12 2015
Amicus Therapeutics (FOLD) Stock Gains Following Pricing of Secondary Offering Jun 12 2015
Momentum bulls pile into Amicus Jun 12 2015
Amicus Therapeutics Prices Underwritten Offering of Common Stock Jun 11 2015
Amicus Therapeutics Prices Underwritten Offering of Common Stock Jun 11 2015
Amicus Therapeutics Announces Public Offering of Common Stock Jun 10 2015
AMICUS THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK